NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics and OvaGene Oncology today announced a manufacturing supply agreement for the design and development of gene expression assays for gynecologic cancers on HTG's platform.
Under the terms of the deal, OvaGene will develop the assays on the HTG Edge System, an automated gene expression platform that delivers multiplexed results on lysed samples in less than one day. HTG launched the platform in 2013 with a portfolio of mRNA assays based on the company's proprietary nuclease protection chemistry.
OvaGene is focused on developing molecular diagnostics for gynecologic cancers, and in a statement CEO Frank Kiesner said that the Edge System "will allow us to expand our specimen type to ascites and smaller samples such as biopsies."
Financial and other terms of the deal were not disclosed.